Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 5/20 | 0.50 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.46 |
| ▸ | NOS1 | P29475 | 2/20 | 0.41 |
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TERT | O14746 | 1/20 | 0.40 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10025483 | 0.86 | NOS1 (0.42) | TLR8NOS1NOS3NOS2TERT | |
| SCHEMBL12598790 | 0.83 | BACE1 (0.54) | TLR8CXCR4NUDT1BACE1 | |
| SCHEMBL3498283 | 0.81 | TLR8 (0.49) | TLR8CXCR4POLBKDM4E | |
| SCHEMBL10025467 | 0.80 | TLR8 (0.48) | TLR8CXCR4KDM4EKMT2A | |
| SCHEMBL30886384 | 0.80 | TLR8 (0.48) | TLR8CXCR4KDM4EKMT2A | |
| SCHEMBL1982004 | 0.79 | CXCR4 (0.73) | TLR8CXCR4POLBKDM4EMEN1 | |
| SCHEMBL23102167 | 0.79 | TLR8 (0.47) | TLR8CXCR4NOS1NOS2KMT2A | |
| SCHEMBL3499273 | 0.76 | TLR7 (0.50) | TLR8CXCR4KMT2A | |
| SCHEMBL3503268 | 0.76 | ACSS2 (0.47) | TLR8CXCR4NUDT1BACE1KMT2A | |
| SCHEMBL14447549 | 0.76 | TLR8 (0.71) | TLR8CXCR4POLBNUDT1BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207173-B2 | Benzimidazoles and analogs thereof as antivirals | ISIS PHARMACEUTICALS, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-8207173-B2 | Benzimidazoles and analogs thereof as antivirals | ISIS PHARMACEUTICALS, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-20100130513-A1 | BENZIMIDAZOLES AND ANALOGS THEREOF AS ANTIVIRALS | ISIS PHARMACEUTICALS, INC. (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100130513-A1 | BENZIMIDAZOLES AND ANALOGS THEREOF AS ANTIVIRALS | ISIS PHARMACEUTICALS, INC. (US) | 2010-05-27 | — | — | US | disclosed |
| US-7642265-B2 | Benzimidazoles and analogs thereof as antivirals | ISIS PHARMACEUTICALS, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-20050124638-A1 | Benzimidazoles and analogs thereof as antivirals | ISIS PHARMACEUTICALS, INC. | 2005-06-09 | — | — | US | disclosed |
| WO-2004050035-A2 | BENZIMIDAZOLES AND ANALOGS THEREOF AS ANTIVIRALS | ISIS PHARMACEUTICALS, INC. (US) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130513-A1 | BENZIMIDAZOLES AND ANALOGS THEREOF AS ANTIVIRALS | ZC3HAV1, NXF1, ZC3HAV1L | TLR8 4042/4885CXCR4 262/4885NOS1 662/4885 |
| US-20050124638-A1 | Benzimidazoles and analogs thereof as antivirals | ZC3HAV1, NXF1, ZC3HAV1L | TLR8 4042/4885CXCR4 262/4885NOS1 662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.